Vaddi Krishna's Form 4 filing
Prelude Therapeutics Inc (PRLD) · filed May 26, 2023
- Accession no.
- 0001562180-23-004517
- Filed
- May 26, 2023
- Trade date
- May 24-25, 2023
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 0 derivative transactions. Open-market purchases total $9.79K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Vaddi KrishnaCIK 0001824633 | Director, Officer (CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 24, 2023 | Common Stock | PPurchaseAcquired | +1,000 | $5.01 | +$5,010 | 1,066,375 | Direct | |
| May 25, 2023 | Common Stock | PPurchaseAcquired | +900 | $5.31 | +$4,779 | 1,067,275 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.